We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-12.48%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$645M
AUM Growth
-$361M
Cap. Flow
-$236M
Cap. Flow %
-36.58%
Top 10 Hldgs %
87.27%
Holding
17
New
–
Increased
–
Reduced
5
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$74.5M
2
NUVL
Nuvalent
NUVL
+$46.1M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$39.3M
4
ANAB icon
AnaptysBio
ANAB
+$24.1M
5
SRRK icon
Scholar Rock
SRRK
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.2B
$95.1M 14.75%
815,176
-653,807
-45% -$74.5M
APGE icon
2
Apogee Therapeutics
APGE
$10.1B
$76.5M 11.87%
2,048,647
– –
SYRE icon
3
Spyre Therapeutics
SYRE
$8.17B
$64.8M 10.06%
4,018,101
– –
ELVN icon
4
Enliven Therapeutics
ELVN
$3.63B
$63M 9.78%
3,202,798
– –
NUVL
5
DELISTED
Nuvalent
NUVL
$51.6M 8%
727,563
-590,101
-45% -$46.1M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.21B
$49M 7.6%
2,700,691
– –
VRDN icon
7
Viridian Therapeutics
VRDN
$1.99B
$46.4M 7.21%
3,445,813
– –
SRRK icon
8
Scholar Rock
SRRK
$6.2B
$44.2M 6.85%
1,374,031
-588,922
-30% -$22.7M
COGT icon
9
Cogent Biosciences
COGT
$6.48B
$37.3M 5.79%
6,225,641
– –
ORKA
10
Oruka Therapeutics
ORKA
$5.01B
$34.6M 5.37%
3,371,922
– –
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$4.7B
$24.5M 3.8%
1,102,248
-1,092,093
-50% -$22.5M
ATXS
12
DELISTED
Astria Therapeutics
ATXS
$19M 2.94%
3,554,129
– –
ZBIO
13
Zenas BioPharma
ZBIO
$1.78B
$15M 2.32%
1,892,806
– –
IKT icon
14
Inhibikase Therapeutics
IKT
$316M
$13.4M 2.08%
6,125,000
– –
BCAX
15
Bicara Therapeutics
BCAX
$1.81B
$10.2M 1.59%
784,170
-499,999
-39% -$6.64M
ANAB icon
16
AnaptysBio
ANAB
$1.6B
– –
-1,816,466
Closed -$24.1M
DAWN
17
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-3,103,448
Closed -$39.3M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2025 Portfolio in Review

As of Q1 2025, Fairmount Funds Management held 17 positions worth $645M, down 36% from $1.01B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Fairmount Funds Management withdrew a net $236M in Q1 2025, closing 2 positions and reducing 5 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $39.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Fairmount Funds Management's biggest Q1 2025 reduction was Axsome Therapeutics, cutting an estimated $74.5M.
  • Fairmount Funds Management fully exited Day One Biopharmaceuticals in Q1 2025, selling an estimated $39.3M.
  • Fairmount Funds Management's ten largest holdings make up 87% of its $645M portfolio in Q1 2025.
  • Fairmount Funds Management opened 0 new positions and closed 2 in Q1 2025.
  • Fairmount Funds Management's portfolio value fell 36% quarter-over-quarter to $645M.

Based on Fairmount Funds Management's 13F filing for Q1 2025, filed 15 May 2025.